可立克(002782.SZ):擬開展金額不超1億美元金融衍生產品交易
格隆匯3月25日丨可立克(002782.SZ)公佈,公司於2021年3月25日召開第三屆董事會第二十五次會議,審議通過了《關於開展金融衍生產品交易業務的議案》。根據公司《金融衍生產品交易管理制度》,結合相關法律、法規和文件的規定和經營需要,公司及子公司以套期保值為目的開展金額不超過1億美元金融衍生產品交易,並授權公司管理層決定及簽署相關交易文件。此次開展的金融衍生產品交易資金來源為公司及子公司自有資金,授權期限自本議案獲得2020年度股東大會審議通過之日起12個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.